Veracyte, Inc. (VCYT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162410,
    "name": "Veracyte, Inc.",
    "stock_name": "Veracyte, Inc.",
    "full_name": "Veracyte, Inc.",
    "name_url": "stocks-analysis/veracyte-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "47.41",
    "chg": 1.25,
    "chgp": "2.71%",
    "dir": 1,
    "prev_price": "46.16",
    "mcapval": "2,553.68",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US92337F1075",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.79 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/veracyte-inc-1162410-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Veracyte, Inc. Experiences Evaluation Adjustment Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veracyte-inc-sees-valuation-grade-shift-from-expensive-to-attractive-amid-price-increase-3667134",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VeracyteInc_valuationdot_3667134.png",
        "date": "2025-11-03 16:00:21",
        "description": "Veracyte, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $36.08. Over the past year, it has returned 6.94%, underperforming the S&P 500. Key metrics include a P/E ratio of 56 and a PEG ratio of 0.12, indicating potential growth."
      },
      {
        "title": "Is Veracyte, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-veracyte-inc-overvalued-or-undervalued-3651077",
        "imagepath": "",
        "date": "2025-10-28 11:12:22",
        "description": "As of 24 October 2025, the valuation grade for Veracyte, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics, particularly with a P/E ratio of 56, a PEG ratio of 0.12, and an EV to EBITDA ratio of 35.87, which are relatively appealing compared to its peers. For instance, iRhythm Technologies, Inc. has a significantly higher P/E of -111.60, while TransMedics Group, Inc. shows a P/E of 50.23, suggesting that Veracyte is better positioned in terms of valuation.\n\nIn terms of recent performance, Veracyte's stock has returned 12.05% over the past year, which is notably lower than the S&P 500's return of 16.90%, but it has outperformed the index over the last three years with a return of 128.70% compared to 78.85%. This performance, alongside its attractive valuation metrics, reinforces the conclusio..."
      },
      {
        "title": "Veracyte, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veracyte-inc-sees-valuation-grade-shift-from-expensive-to-attractive-amid-stock-price-increase-3649110",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VeracyteInc_valuationdot_3649110.png",
        "date": "2025-10-27 16:01:49",
        "description": "Veracyte, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 56 and a price-to-book value of 1.80. The company exhibits a unique growth outlook with a PEG ratio of 0.12, while its stock performance reflects a 1-week return of 2.51% and a 128.70% return over three years."
      },
      {
        "title": "Is Veracyte, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-veracyte-inc-overvalued-or-undervalued-3647586",
        "imagepath": "",
        "date": "2025-10-27 11:12:38",
        "description": "As of 24 October 2025, the valuation grade for Veracyte, Inc. moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics. Key valuation ratios include a P/E ratio of 56, a Price to Book Value of 1.80, and an EV to EBITDA of 35.87, which suggest that while the stock has a high earnings multiple, it may still offer value relative to its growth potential.\n\nIn comparison to its peers, Veracyte's P/E ratio of 50.97 is more favorable than that of iRhythm Technologies, which has a risky valuation with a P/E of -111.60, and TransMedics Group, which is fairly valued at a P/E of 50.23. Despite recent challenges, Veracyte has outperformed the S&P 500 over the 1-week and 1-month periods, with returns of 2.51% and 12.39%, respectively, although it has lagged behind in the year-to-date and 5-year returns...."
      },
      {
        "title": "Is Veracyte, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-veracyte-inc-overvalued-or-undervalued-3646123",
        "imagepath": "",
        "date": "2025-10-26 11:09:05",
        "description": "As of 24 October 2025, the valuation grade for Veracyte, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 56, a Price to Book Value of 1.80, and a PEG Ratio of 0.12, suggesting strong growth potential relative to its price. In comparison, peers such as TransMedics Group, Inc. have a P/E of 50.23 and an EV to EBITDA of 37.01, while iRhythm Technologies, Inc. shows a risky valuation with a P/E of -111.60.\n\nDespite a challenging year-to-date return of -7.25% compared to the S&P 500's 15.47%, Veracyte has demonstrated strong performance over three years with a return of 128.70%, outpacing the benchmark's 78.85%. This performance, alongside its attractive valuation metrics, reinforces the view that Veracyte is currently undervalued...."
      },
      {
        "title": "Veracyte, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veracyte-inc-sees-valuation-grade-shift-from-expensive-to-attractive-amid-market-performance-3640995",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VeracyteInc_valuationdot_3640995.png",
        "date": "2025-10-20 17:07:02",
        "description": "Veracyte, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 56 and a low PEG ratio of 0.12, suggesting potential growth. Compared to peers, its performance metrics vary, with a year-to-date return of -9.52%, but a notable three-year return of 113.53%."
      },
      {
        "title": "Veracyte, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veracyte-inc-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-stock-price-increase-3640455",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VeracyteInc_technicaldot_3640455.png",
        "date": "2025-10-20 15:23:58",
        "description": "Veracyte, Inc. has recently revised its evaluation amid changing market conditions. The stock, priced at $35.83, has shown a 4.43% return over the past year, lagging behind the S&P 500. Despite recent challenges, Veracyte has achieved a notable 113.53% return over the last three years."
      },
      {
        "title": "Veracyte, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/veracyte-inc-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-stock-price-increase-3601224",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VeracyteInc_technicaldot_3601224.png",
        "date": "2025-10-07 20:28:00",
        "description": "Veracyte, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $36.04, with a 9.74% return over the past year, lower than the S&P 500. However, it has achieved a 94.92% return over three years, outperforming the index during that period."
      },
      {
        "title": "Is Veracyte, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-veracyte-inc-technically-bullish-or-bearish-3599114",
        "imagepath": "",
        "date": "2025-10-07 12:18:58",
        "description": "As of 3 October 2025, the technical trend for Veracyte, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, supported by bullish Bollinger Bands and a mildly bullish monthly Dow Theory. However, the monthly MACD and KST are mildly bearish, and the daily moving averages indicate a mildly bearish stance. The stock has outperformed the S&P 500 over the past week and month, returning 7.23% and 11.13% respectively, while it has underperformed on a year-to-date and one-year basis. Overall, the current technical stance is mildly bullish, driven primarily by strong weekly indicators despite some mixed signals in longer time frames...."
      }
    ],
    "total": 18,
    "sid": "1162410",
    "stock_news_url": "https://www.marketsmojo.com/news/veracyte-inc-1162410"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Veracyte, Inc. Experiences Evaluation Adjustment Amid Competitive Market Landscape

2025-11-03 16:00:21

Veracyte, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, currently priced at $36.08. Over the past year, it has returned 6.94%, underperforming the S&P 500. Key metrics include a P/E ratio of 56 and a PEG ratio of 0.12, indicating potential growth.

Is Veracyte, Inc. overvalued or undervalued?

2025-10-28 11:12:22

As of 24 October 2025, the valuation grade for Veracyte, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics, particularly with a P/E ratio of 56, a PEG ratio of 0.12, and an EV to EBITDA ratio of 35.87, which are relatively appealing compared to its peers. For instance, iRhythm Technologies, Inc. has a significantly higher P/E of -111.60, while TransMedics Group, Inc. shows a P/E of 50.23, suggesting that Veracyte is better positioned in terms of valuation. In terms of recent performance, Veracyte's stock has returned 12.05% over the past year, which is notably lower than the S&P 500's return of 16.90%, but it has outperformed the index over the last three years with a return of 128.70% compared to 78.85%. This performance, alongside its attractive valuation metrics, reinforces the conclusio...

Veracyte, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-27 16:01:49

Veracyte, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 56 and a price-to-book value of 1.80. The company exhibits a unique growth outlook with a PEG ratio of 0.12, while its stock performance reflects a 1-week return of 2.51% and a 128.70% return over three years.

Is Veracyte, Inc. overvalued or undervalued?

2025-10-27 11:12:38

As of 24 October 2025, the valuation grade for Veracyte, Inc. moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics. Key valuation ratios include a P/E ratio of 56, a Price to Book Value of 1.80, and an EV to EBITDA of 35.87, which suggest that while the stock has a high earnings multiple, it may still offer value relative to its growth potential. In comparison to its peers, Veracyte's P/E ratio of 50.97 is more favorable than that of iRhythm Technologies, which has a risky valuation with a P/E of -111.60, and TransMedics Group, which is fairly valued at a P/E of 50.23. Despite recent challenges, Veracyte has outperformed the S&P 500 over the 1-week and 1-month periods, with returns of 2.51% and 12.39%, respectively, although it has lagged behind in the year-to-date and 5-year returns....

Is Veracyte, Inc. overvalued or undervalued?

2025-10-26 11:09:05

As of 24 October 2025, the valuation grade for Veracyte, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its current metrics, with a P/E ratio of 56, a Price to Book Value of 1.80, and a PEG Ratio of 0.12, suggesting strong growth potential relative to its price. In comparison, peers such as TransMedics Group, Inc. have a P/E of 50.23 and an EV to EBITDA of 37.01, while iRhythm Technologies, Inc. shows a risky valuation with a P/E of -111.60. Despite a challenging year-to-date return of -7.25% compared to the S&P 500's 15.47%, Veracyte has demonstrated strong performance over three years with a return of 128.70%, outpacing the benchmark's 78.85%. This performance, alongside its attractive valuation metrics, reinforces the view that Veracyte is currently undervalued....

Veracyte, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape

2025-10-20 17:07:02

Veracyte, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 56 and a low PEG ratio of 0.12, suggesting potential growth. Compared to peers, its performance metrics vary, with a year-to-date return of -9.52%, but a notable three-year return of 113.53%.

Veracyte, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators

2025-10-20 15:23:58

Veracyte, Inc. has recently revised its evaluation amid changing market conditions. The stock, priced at $35.83, has shown a 4.43% return over the past year, lagging behind the S&P 500. Despite recent challenges, Veracyte has achieved a notable 113.53% return over the last three years.

Veracyte, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals

2025-10-07 20:28:00

Veracyte, Inc. has recently revised its evaluation amid changing market conditions. The stock is priced at $36.04, with a 9.74% return over the past year, lower than the S&P 500. However, it has achieved a 94.92% return over three years, outperforming the index during that period.

Is Veracyte, Inc. technically bullish or bearish?

2025-10-07 12:18:58

As of 3 October 2025, the technical trend for Veracyte, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, supported by bullish Bollinger Bands and a mildly bullish monthly Dow Theory. However, the monthly MACD and KST are mildly bearish, and the daily moving averages indicate a mildly bearish stance. The stock has outperformed the S&P 500 over the past week and month, returning 7.23% and 11.13% respectively, while it has underperformed on a year-to-date and one-year basis. Overall, the current technical stance is mildly bullish, driven primarily by strong weekly indicators despite some mixed signals in longer time frames....

View All News